洛铂联合榄香烯治疗肺癌恶性胸腔积液的临床研究

Clinical Study of Lobaplatin and Elemene in the Treatment of Malignant Pleural Effusion of Lung Cancer

目的探讨胸腔灌注洛铂联合榄香烯与洛铂单药治疗肺癌恶性胸腔积液的临床疗效。方法回顾90例肺癌恶性胸腔积液患者,分为观察组和对照组,每组患者45例。观察组给予利多卡因200 mg,地塞米松10 mg,洛铂30 mg,榄香烯500 mg;对照组给予利多卡因200 mg,洛铂30 mg。比较两组患者在临床疗效、生活质量及并发症发生率。结果观察组PR、SD及总有效率明显高于对照组(P<0.05)。观察组CR、PD与对照组无显著差异(P>0.05)。观察组较对照组生活质量明显改善(P<0.05)。观察组较对照组疼痛发生率及并发症总发生率高(P<0.05);观察组与对照组发热发生率及恶心呕吐并发症发生率无显著差异(P>0.05)。结论洛铂联合榄香烯胸腔内灌注治疗肺癌恶性胸腔积液较洛铂单药临床疗效好,患者的生活质量高,值得临床应用。

Objective To investigate the clinical efficacy of intrathoracic infusion of lobaplatin combined with elemene and lobaplatin in the treatment of malignant pleural effusion of lung cancer.Methods 90 patients with malignant pleural effusion of lung cancer were reviewed and divided into observation group and control group,with 45 patients in each group.The observation group was given 200 mg of lidocaine,10 mg of dexamethasone,30 mg of lobaplatin,and 500 mg of elemene;the control group was given 200 mg of lidocaine and 30 mg of lobaplatin.Compare the clinical efficacy,quality of life,and incidence of complications between the two groups of patients.Results The PR,SD,and total effective rates in the observation group were significantly higher than those in the control group(P<0.05).There was no significant difference between CR and PD in the observation group and the control group(P>0.05).The quality of life in the observation group was significantly improved compared with the control group(P<0.05).The observation group had a higher incidence of pain and total complications than the control group(P<0.05);there was no significant difference in the incidence of fever and nausea and vomiting complications between the observation group and the control group(P>0.05).Conclusion Intrapleural infusion of lobaplatin combined with elemene for lung cancer malignant pleural effusion had better clinical efficacy than lobaplatin as a single drug,and the quality of life of patients was high,which deserves clinical application.